bpc-157 mcas bpc 157 Canada Mast Cell Activation Syndrome -

A favorable recommendation from the FDA's Pharmacy Compounding Advisory Committee (PCAC), scheduled for review in July 2026, followed by formal rulemaking, is required before legal compounding access is restored

Please see product label for full prescribing information

Clinical trial activity has been registered but human safety data remains limited

Red flags when evaluating suppliers include: prices dramatically below market rates, absence of third-party testing documentation, vague or missing contact information, no batch numbers or lot tracking, poor packaging or labeling, and pressure to buy immediately

Risks and Limitations Handling: BPC-157 should be handled by trained personnel in a controlled research setting, with standard PPE and biosafety protocols